Improvement of Treatment Outcomes for Metastatic Pancreatic Cancer: A Real-world Data Analysis.
Adult
Aged
Aged, 80 and over
Albumins
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Deoxycytidine
/ administration & dosage
Drug Combinations
Female
Fluorouracil
/ administration & dosage
Humans
Irinotecan
Leucovorin
/ administration & dosage
Male
Middle Aged
Neoplasm Metastasis
Organometallic Compounds
/ administration & dosage
Oxaliplatin
Paclitaxel
/ administration & dosage
Pancreatic Neoplasms
/ drug therapy
Progression-Free Survival
Treatment Outcome
Gemcitabine
FOLFIRINOX
Metastatic pancreatic cancer
chemotherapy
gemcitabine
nab-paclitaxel
real-world data
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
08
10
2018
revised:
11
11
2018
accepted:
15
11
2018
entrez:
28
12
2018
pubmed:
28
12
2018
medline:
5
4
2019
Statut:
ppublish
Résumé
FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, oxaliplatin) and gemcitabine plus nab-paclitaxel therapy have recently been introduced for the treatment of metastatic pancreatic cancer. Herein, overall treatment outcomes of metastatic pancreatic cancer after introduction of FOLFIRINOX and gemcitabine plus nab-paclitaxel therapy were evaluated, in daily practice. Metastatic pancreatic cancer patients (n=321) who started systemic chemotherapy between January 2011 and December 2016 were included and were divided into two groups: group A (2011-2013) and group B (2014-2016). Treatment outcomes were evaluated retrospectively. Patient characteristics were similar between the two groups except for the rates of distant lymph node metastasis and peritoneal metastasis. The preferred regimens in groups A and B were gemcitabine monotherapy and gemcitabine plus nab-paclitaxel therapy, respectively. The response rates, median progression-free survival, and median overall survival of groups A and B were 7.8% and 28.4% (p<0.01), 3.1 months and 5.4 months (p<0.01), and 6.7 months and 10.2 months (p<0.01), respectively. Overall treatment outcomes for metastatic pancreatic cancer were significantly improved after introduction of FOLFIRINOX and gemcitabine plus nab-paclitaxel combination therapy in daily practice.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, oxaliplatin) and gemcitabine plus nab-paclitaxel therapy have recently been introduced for the treatment of metastatic pancreatic cancer. Herein, overall treatment outcomes of metastatic pancreatic cancer after introduction of FOLFIRINOX and gemcitabine plus nab-paclitaxel therapy were evaluated, in daily practice.
PATIENTS AND METHODS
METHODS
Metastatic pancreatic cancer patients (n=321) who started systemic chemotherapy between January 2011 and December 2016 were included and were divided into two groups: group A (2011-2013) and group B (2014-2016). Treatment outcomes were evaluated retrospectively.
RESULTS
RESULTS
Patient characteristics were similar between the two groups except for the rates of distant lymph node metastasis and peritoneal metastasis. The preferred regimens in groups A and B were gemcitabine monotherapy and gemcitabine plus nab-paclitaxel therapy, respectively. The response rates, median progression-free survival, and median overall survival of groups A and B were 7.8% and 28.4% (p<0.01), 3.1 months and 5.4 months (p<0.01), and 6.7 months and 10.2 months (p<0.01), respectively.
CONCLUSION
CONCLUSIONS
Overall treatment outcomes for metastatic pancreatic cancer were significantly improved after introduction of FOLFIRINOX and gemcitabine plus nab-paclitaxel combination therapy in daily practice.
Identifiants
pubmed: 30587635
pii: 33/1/271
doi: 10.21873/invivo.11471
pmc: PMC6364051
doi:
Substances chimiques
130-nm albumin-bound paclitaxel
0
Albumins
0
Drug Combinations
0
Organometallic Compounds
0
folfirinox
0
Oxaliplatin
04ZR38536J
Deoxycytidine
0W860991D6
Irinotecan
7673326042
Paclitaxel
P88XT4IS4D
Leucovorin
Q573I9DVLP
Fluorouracil
U3P01618RT
Gemcitabine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
271-276Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
J Clin Oncol. 2007 May 20;25(15):1960-6
pubmed: 17452677
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
J Clin Oncol. 2013 May 1;31(13):1640-8
pubmed: 23547081
JAMA. 2013 Apr 3;309(13):1359-67
pubmed: 23549581
J Hepatobiliary Pancreat Sci. 2013 Aug;20(6):590-600
pubmed: 23660962
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
Lancet. 2016 Feb 6;387(10018):545-57
pubmed: 26615328
Eur J Cancer. 2016 Jan;52:85-91
pubmed: 26655559
J Clin Oncol. 2016 Aug 10;34(23):2784-96
pubmed: 27247222
J Gastrointest Oncol. 2016 Jun;7(3):469-78
pubmed: 27284481
World J Gastroenterol. 2016 Nov 28;22(44):9694-9705
pubmed: 27956793
Cancer Chemother Pharmacol. 2017 Aug;80(2):371-375
pubmed: 28664225
Cancer. 2018 Jun 1;124(11):2289-2298
pubmed: 29461625
BMJ Open Gastroenterol. 2018 Feb 11;5(1):e000187
pubmed: 29527313
Cancer Chemother Pharmacol. 2018 Jun;81(6):1017-1023
pubmed: 29633005
Sci Rep. 2018 Jun 6;8(1):8666
pubmed: 29875415
BMC Cancer. 2018 Jul 18;18(1):747
pubmed: 30021548
J Clin Oncol. 1997 Jun;15(6):2403-13
pubmed: 9196156